acquisit achillion share under-valued
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
methodolog valu compani
oct narrow-moat alexion announc enter
agreement purchas achillion small biotech
compani focus treatment complement-medi
diseas million roughli million net
cash acquir fund cash hand achillion
pipelin compos danicopan
oral factor inhibitor phase next-
gener factor inhibitor phase addit
per achillion share alexion offer sharehold two
conting valu right one event approv
danicopan one initi phase trial
model adjust acquisit
decreas fair valu estim single-digit
percentag off-set time valu money
sinc last updat maintain fair valu
estim per share stand narrow
moat rate support soliri ultomiri
complement-medi rare ultra-rar diseas
achillion portfolio line alexion core focu
complement-medi diseas util differ
mechan action buy-out also bring potenti
competitor alexion fold see deal
complementari defens danicopan studi
add-on therapi could potenti reduc
amount requir soliri transfus patient
pnh howev ultomiri alreadi offer patient
significantli fewer transfus lower price point
view danicopan substanti threat alexion
plan develop danicopan patient pnh
experienc extravascular hemolysi take
soliri manag indic less
patient acquisit materi alter sale
project pnh
howev adjust model add modest revenu
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria atyp hemolyt
urem syndrom gener myasthenia gravi next-gener
ultomiri recent approv paroxysm nocturn hemoglobinuria
strensiq kanuma target ultrarar metabol diseas alexion
rare diseas high unmet need
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
expir soliri patent like entri
biosimilar howev seen sign manag
combat competit headwind recent
popul achillion deal compani announc
last week agreement stealth biotherapeut
exclus option co-develop commerci
elamipretid mitochondri diseas step
approv therapi present blockbust
pmm difficult diagnos often misdiagnos
could present constraint commerci
impact size elig popul initi
estim pmm present blockbust opportun
includ estim model unless alexion
exercis option see phase result expect
first half next year
contribut achillion danicopan glomerulopathi
ultra-rar kidney diseas character
progress kidney damag caus overactiv
complement altern pathway approv
treatment option despit support care patient
progress kidney failur face relaps even
kidney transplant affect patient
 approv treatment think area
high unmet need fit well alexion rare-diseas
portfolio earli stage think indic
present blockbust market opportun addit
like alexion portfolio expand address differ
target within complement pathway bolster
competit posit space
note deal manag expect
close first half next year face uncertainti
wait hear regul watch
similar concern rais bristol-celgen
deal result celgen divest otezla
anti-trust concern combin portfolio psoriasi
feder trade commiss action around
bristol acquisit celgen recent delay
roch acquisit spark could see new
pattern tighter scrutini around clinic candid
alexion alreadi domin hold complement-
mediat diseas achillion complement candid
still earli develop respons analyst
question call manag argu achillion
competit
address new group patient pnh patient
patient mostli agre sentiment
still believ deal may face scrutini regul
complementari
alexion acquir candid otherwis could
pose competitor road support neg
moat trend rate think five year
alexion intang asset weaker posit due
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
